# Nexalin Technology, Inc. (NXL) · Edgar & Edgarette company card

> Nexalin Technology (NXL) grew revenue 78.8% in FY2025 to $0 million, operating margin -2782% against a 7.5% median for electromedical & electrotherapeutic apparatus, equity 80.9% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1527352 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/NXL) · [JSON](https://www.pops4.com/boards/company/NXL.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $301,647 |
| Revenue growth, 1 year | 78.8% |
| Revenue growth per year | 20.3% |
| Operating margin | -2781.7% (prior year -4596.1%) |
| Net margin | -2725.8% |
| Operating cash flow | −$5M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $654,783 |
| Long-term debt | — |
| Total assets | $5M |
| Total equity | $4M |
| Equity ÷ assets | 80.9% |
| Return on equity | -219.4% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -68.21 (distress zone)
- Piotroski F: 5 of 9 (middling)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative (-$5.0M in FY2025); operating loss: a margin of -2781.7% in FY2025; revenue is hard to predict: its 80% range is ±48%

## Edgarette's reading

Exposure: revenue $302K (FY2025). Experience: revenue up 78.8% on the year, up 20.3% a year over 4 years; operating margin -2781.7%, up from -4596.1%. Soundness: equity 80.9% of assets, return on equity -219.4%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $211K and $596K next year (method v4.1: its own 2-year record of growth weighed at 25% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $197K to $642K. A statistical range, not company guidance. Against peers (13 filers, $50M+ revenue, electromedical & electrotherapeutic apparatus): operating margin -2781.7% against a 7.5% median; growth 78.8% against 8.3%.

Range logged 2026-09-24, receipt 14eea4f722c6d1dd, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 4, latest 2026-09-28 ([filing](https://www.sec.gov/Archives/edgar/data/1527352/000182912626010495/0001829126-26-010495-index.htm))
- Item 5.02 Director or officer change: 1, latest 2026-09-02 ([filing](https://www.sec.gov/Archives/edgar/data/1527352/000182912626009659/0001829126-26-009659-index.htm))

## Recent filings

- 8-K · filed 2026-10-01 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1527352/000182912626010686/0001829126-26-010686-index.htm)
- 8-K · filed 2026-10-01 · 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1527352/000182912626010685/0001829126-26-010685-index.htm)
- 8-K · filed 2026-09-28 · 3.01 Notice of Delisting or Failure to Satisfy a Listing Rule · [filing](https://www.sec.gov/Archives/edgar/data/1527352/000182912626010495/0001829126-26-010495-index.htm)
- S-1 · filed 2026-09-03 · [filing](https://www.sec.gov/Archives/edgar/data/1527352/000182912626009723/0001829126-26-009723-index.htm)
- 8-K · filed 2026-09-02 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/1527352/000182912626009659/0001829126-26-009659-index.htm)
- 8-K · filed 2026-08-27 · 3.03 Material Modifications to Rights of Security Holders; 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1527352/000182912626009387/0001829126-26-009387-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001527352.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1527352

## Cite

POPS4, Edgar & Edgarette: Nexalin Technology, Inc. (NXL) company card, from the company's own SEC filings, accessed 2026-11-05, https://www.pops4.com/boards/company/NXL. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.